MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on November 28, 2006; DOI: 10.1124/mol.106.028944


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.106.028944v1
71/3/759    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huang, X.-P.
Right arrow Articles by Ellis, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huang, X.-P.
Right arrow Articles by Ellis, J.


Received for publication July 18, 2006.
Revised November 10, 2006.
Accepted for publication November 28, 2006.

Mutational disruption of a conserved disulfide bond in muscarinic acetylcholine receptors attenuates positive homotropic cooperativity between multiple allosteric sites and has subtype-dependent effects on the affinities of muscarinic allosteric ligands

Xi-Ping Huang 1 John Ellis 1*

1 Hershey Medical Center

* Address correspondence to: E-mail: jxe11{at}psu.edu

Abstract

The 2nd outer loop (o2) of muscarinic acetylcholine receptors (mAChRs) contains a highly conserved cysteine residue that is believed to participate in a disulfide bond and is flanked on either side by epitopes that are critical to the binding of many muscarinic allosteric modulators. We determined the allosteric binding parameters of the modulators gallamine, W84, and tetrahydroaminoacridine (THA) at M2 and M3 mAChRs in which these cysteine residues had been mutated to alanines. THA is known to bind to mAChRs with a strong positive homotropic cooperativity (a Hill slope of about 2) that implies that it must interact with multiple allosteric sites. The disulfide cysteine mutations in M2 receptors reduced the allosteric potencies of the tested modulators as if the critical adjacent residue (Tyr177) itself had been mutated. However, in M3 receptors, the disulfide cysteine mutations had no effect on the potencies of gallamine or W84, and even increased the potency of THA. Most interestingly, the strong positive homotropic interactions of THA at both M2 and M3 receptors were markedly reduced by the cysteine mutations. Additionally, gallamine also displayed positive homotropic cooperativity in its interactions with M3 receptors (but not M2 receptors) and this cooperativity was not evident in the cysteine mutants. Thus, it appears that these cysteine residues play a role in linking cooperating allosteric sites, although it is not possible at the present time to say whether these multiple sites lie within one receptor or on two linked receptors of a dimer or higher order oligomer.


Key words: Muscarinic cholinergic, Mutagenesis/Chimeric approaches, Receptor binding studies


This article has been cited by other articles:


Home page
Circ. Res.Home page
L. Zhang, A. Hu, H. Yuan, L. Cui, G. Miao, X. Yang, L. Wang, J. Liu, X. Liu, S. Wang, et al.
A Missense Mutation in the CHRM2 Gene Is Associated With Familial Dilated Cardiomyopathy
Circ. Res., June 6, 2008; 102(11): 1426 - 1432.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
J. A. Goodwin, E. C. Hulme, C. J. Langmead, and B. G. Tehan
Roof and Floor of the Muscarinic Binding Pocket: Variations in the Binding Modes of Orthosteric Ligands
Mol. Pharmacol., December 1, 2007; 72(6): 1484 - 1496.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics